


NIC INTERNATIONAL CONFERENCE 2023

SINGAPORE

Healthcare, Geopolitics and the Disruptors

Four Seasons Hotel Singapore
4 - 5 May 2023

Programme Booklet



NIC INTERNATIONAL CONFERENCE 2023

SINGAPORE



Healthcare, Geopolitics and the Disruptors

Contents

Conference Programme

Thursday, 4 May 2023

2

Friday, 5 May 2023

6

Speakers' and Moderators' Biographies

12

Acknowledgements


38

General Information

38

Useful Contacts

39



Conference Programme

Thursday, 4 May 2023

Time	Conference Agenda
8:30am – 9:30am	Registration
9:30am – 10:30am	Welcome by Professor Kishore MAHBUBANI <i>Chairman, NUS Medicine International Council (NIC)</i> Opening address by NIC Chairman: Is the Asian century really coming? The world today faces a huge contradiction. On the one hand, the data shows that power, especially economic power, is shifting to Asia. On the other hand, the established powers, especially in the trans-Atlantic alliance, refuse to acknowledge that a major transition in world history is happening. The Western powers continue to cling to old privileges, like the headships of the World Bank and the IMF. The US will also step up its efforts to stop the rise of China. So, will we witness an Asian century? And, if it comes, what will the shape and texture of such an Asian century be? Will Asian powers try to dominate the world? Or will they work with the existing world order? Will multilateral institutions such as the World Bank and IMF continue to be dominated by the West? In short, major questions have to be addressed as we try to understand the new world hurtling towards us.
10:30am – 11:00am	Morning tea break



Time	Conference Agenda
11:00am – 12:00pm	<p>Keynote by Mr Casey MACE: US engagement with Singapore, the region, and the world <i>Deputy Chief of Mission, US Embassy in Singapore</i></p> <p>US Embassy Deputy Chief of Mission Casey Mace will discuss the Biden Administration’s relationship with Singapore as well as its approach to relations with East Asia and the World as the United States works with friends, allies, and partners to tackle shared challenges ranging from climate change to defending the territorial integrity of sovereign states.</p> <p>Moderator: Professor Kishore MAHBUBANI, <i>NIC Chairman</i></p>
12:00pm – 1:45pm	<p>Lunch break</p>
1:45pm – 2:00pm	<p>Disruptive tech showcase: Sustainable, cost-effective and biodegradable materials to replace petroleum plastics by Mr Ryan ADOLPHSON, <i>Chief Operating Officer, RWDC Industries, United States</i></p> <p>The world is overwhelmed by plastics and plastic pollution is causing significant negative impact on human health and the environment. The traditional Three Rs (Reduce, Reuse, and Recycle) are inadequate to address the problem and a fourth R-Replace is needed. Products made with RWDC’s Solon™ PHA biopolymer resins feel and cost like plastic but biodegrade in the natural environment with no negative impact on human health. Solon™ seamlessly replaces petrol-based plastic in products we use everyday. RWDC produces PHA polymers and resins from renewable resources with the most scalable, efficient, and cost-effective process in the industry today.</p>
2:00pm – 2:25pm	<p>Update on NUS Medicine by Professor Yap Seng CHONG <i>Dean, Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine)</i></p>

Thursday, 4 May 2023

Time	Conference Agenda
2:25pm – 3:30pm	NIC members' meeting
3:30pm – 4:00pm	Afternoon tea break
4:00pm – 5:00pm	Longevity panel <p>Over the past 150 years, progress in medical care has allowed us to live longer but not necessarily healthier lives, opening a gap between lifespan (the total number of years we live) and healthspan (the years we live in good health). We're now facing an ever-increasing problem of an ageing population that comes with both social and economic implications. Closing the gap between life expectancy and disease-free years should therefore be of utmost priority. Advancements in longevity research have skyrocketed over the past couple of decades, culminating in the elucidation of common molecular mechanisms of ageing that could now be used to develop safe and effective interventions aimed at extending healthspan.</p> <p>Panellists:</p> <ul style="list-style-type: none">• Healthy longevity for all: Democratising longevity by bridging the gap between science and business innovation by Dr Elisabeth ROIDER, <i>Chief Scientific and Medical Officer and Partner, Maximon, Switzerland</i> (Hybrid participation) <p>Given that one of the major challenges that lies ahead is to translate this scientific innovation into products and services available to the wider public, Dr Roider will discuss the challenges of bringing science innovation to the market and why strategic investments in this sector have the potential to not only allow ageing populations to live healthier and more active lives but also provide a systemic relief from the economic burden associated with an ageing population.</p>



Time	Conference Agenda
4:00pm – 5:00pm (continued)	<ul style="list-style-type: none"><li data-bbox="342 293 852 416">• From sick-care to health-care with hyper personalised prevention by Dr Rob KONRAD, <i>Chief Executive Officer and Co-Founder, Biolytica, Switzerland</i> Traditional “Sick-Care” systems, focussed on costly disease management, are financially and ethically unsustainable, exacerbating healthcare inequalities. Preventive healthcare and longevity are becoming increasingly significant trends. The key to disease prevention and health optimisation is hyperpersonalised care. Dr Rob Konrad’s talk will highlight Biolytica’s revolutionary approach to health. The company’s experts employ cutting-edge technology and data analysis to help people enhance their well-being by decoding bodily information and crafting tailored health journeys, factoring in genomics, biomarkers, and daily activity patterns.<li data-bbox="342 900 962 1023">• Data-driven longevity: Unlocking the power of usable health data by Dr Suhina SINGH, <i>Co-founder and Chief Executive Officer, Jonda Health, Singapore</i> Dr Singh will discuss the critical importance of data normalisation and interoperability to facilitate data-driven longevity. <p data-bbox="342 1187 969 1299">Moderator: Professor Brian KENNEDY, <i>Distinguished Professor in Biochemistry and Physiology, Director of the Healthy Longevity Translational Research Programme, and the Asian Centre for Reproductive Longevity and Equality, NUS Medicine.</i></p>
5:00pm – 6:00pm	Free and easy time
6:00pm – 8:30pm	Welcome dinner

Friday, 5 May 2023

Time	Conference Agenda
9:00am – 9:30am	Registration
9:30am – 10:30am	Russo-Ukrainian war: Limits of Western shock and awe over economic sanctions by Professor Steven ROSEFELDE , <i>Professor of Economics, University of North Carolina, Chapel Hill, United States</i> (Hybrid participation) The paper rigorously identifies the maximum theoretical impact of Western economic sanctions, and the mathematical conditions for softening the blow. Russia weathered sanctions easily and Professor Rosefelde will explain why 2023 will bring more of the same. Washington and Brussels know this, but are in a state of acute denial. Xi Jinping is sure to take note of the fact that the sanctions from hell were ineffectual, and adjust his foreign policy accordingly. Professor Rosefelde will address the policy consequences of draconian Western economic sanctions and other pertinent military economic issues during the discussion period. Moderator: Professor Kishore MAHBUBANI , <i>NIC Chairman</i>
10:30am – 11:00am	Morning tea break



Time	Conference Agenda
11:00am – 12:00pm	<p>“Consumptionomics” for the Asian Century: Managing within constraints by Mr Chandran NAIR, <i>Founder and Chief Executive Officer, Global Institute For Tomorrow (GIFT), Hong Kong</i></p> <p>Mr Nair argues that six billion Asians in 2050 cannot and should not aspire to live Western lifestyles. The Western model of consumption-led economic growth will result in catastrophic outcomes at a time when resource constraints are only too apparent. Calling for bans on some forms of consumption, re-pricing of resources, and for the state to play the all-important role in promoting economic activity that is equitable and sustainable, Mr Nair advocates the search for new business models that do not thrive on promoting relentless consumption by under-pricing resources and externalising costs. Instead economies should be focussed on redefining prosperity so as to meet the majority’s needs in critical areas of food (safe, secure), water and sanitation, affordable housing, low carbon energy, basic healthcare, and education.</p> <p>Moderator: Mr Narinder SINGH, <i>Co-Founder and Director, Avina Holdings</i></p>
12:00pm – 2:00pm	<p>Lunch dialogue with Mr George YEO <i>Former Minister of Foreign Affairs, Singapore</i></p> <p>Moderator: Professor Kishore MAHBUBANI, <i>NIC Chairman</i></p>

Friday, 5 May 2023

Time	Conference Agenda
2:00pm – 3:00pm	<p>Global economic transformation by Mr Mark CUTIS, <i>Non-Executive Chairman and Managing Partner, CCHL</i></p>
3:00pm – 3:15pm	<p>Disruptive tech showcase: A non-invasive urine test for bladder cancer detection by Dr Kian Chung LEE, <i>Chief Executive Officer, BioCheetah Pte Ltd, Singapore</i></p> <p>According to GLOBOCAN cancer database 2020, bladder cancer is the sixth most common cancer worldwide among males, with an estimated 573,000 new cases in 2020 for both sexes. This is an increase of 33% new incidence cases compared to the 430,000 cases in 2012. Current standard of care in bladder cancer diagnosis is via the use of cystoscopy. Being an invasive diagnostic procedure, which requires local or general anaesthesia, there may be risks of infection, bleeding, perforation, or complications from the anaesthesia. As with most cancers, survival is greatly dependent upon the stage in which the cancer has been diagnosed. Various unmet clinical needs exist in bladder cancer diagnosis which prompts the development of new approaches. BioCheetah intends to fill the diagnostic gap by providing non-invasive diagnostic tests that are specific and sensitive towards bladder cancer detection.</p>



Time	Conference Agenda
3:15pm – 4:00pm	<p>Global partnerships to accelerate global solutions by Mr Toby SIMON, <i>Chief Executive Officer, Synergia Foundation, Synergia Bio Sciences, India</i></p> <p>The world is faced with healthcare, climate and inequality challenges. Synergia Bio Sciences will present advances in drug delivery including an innovative nano emulsion drug delivery platform designed for targeted drug delivery of any lyophilic drug. The platform has the potential to deliver a range of drugs including anti-psychotic, anti-emetics, anti-epileptics, anti-pyretic, oncology, vaccines, and insulin. The platform has received 20-year patents in the US, Japan, Europe, and India.</p> <p>Moderator: Dr Yvanka GILLIAM, <i>Chief Executive Officer and Founder, Clinical Research Advancement, Singapore</i></p>
4:00pm – 4:30pm	Afternoon tea break


Friday, 5 May 2023

Time	Conference Agenda
4:30pm – 5:30pm	<p data-bbox="385 292 768 320">Cutting edge technology showcase</p> <p data-bbox="385 357 493 384">Panellists:</p> <ul data-bbox="385 389 922 448" style="list-style-type: none"><li data-bbox="385 389 922 448">• Harnessing Neoantigens: The future of cancer immunotherapy <p data-bbox="415 453 967 512">by Dr Gloryn CHIA, <i>Assistant Professor, Department of Pharmacy, Faculty of Science, NUS</i></p> <p data-bbox="415 549 1001 863">In recent years, immunotherapy has emerged as a promising approach in cancer treatment. One of the latest strategies involves treating cancers with cancer vaccines that increase recognition of tumours by immune cells. These vaccines are highly specific and have low off-target toxicity, which make them a very attractive option. This talk will focus on the development of cancer vaccines for treating solid tumours and discuss the challenges and opportunities for using these vaccines in cancer treatment.</p> <ul data-bbox="385 900 729 928" style="list-style-type: none"><li data-bbox="385 900 729 928">• The digital health landscape <p data-bbox="415 933 986 992">by Dr Snehal PATEL, <i>Managing Director, Saena Partners, Singapore</i></p> <p data-bbox="415 1029 994 1152">Dr Patel will be presenting an overview of the digital health market, the key technology disruptors (Chat GPT, etc.), and the supposed direction of these digital health innovations.</p>



Time	Conference Agenda
4:30pm – 5:30pm (continued)	<ul style="list-style-type: none"><li data-bbox="340 293 934 352">• Ending cancer as the world knows it through liquid biopsy by Dr Min-Han TAN, <i>Chief Executive Officer and Medical Director, Singapore</i> <p data-bbox="368 453 947 703">Asia is facing a \$10 trillion cancer burden in the next 30 years (JAMA Oncology, 2023). President Biden has issued a Cancer Moonshot call in the US, with multi-cancer early detection (MCED) blood tests as a key path to halving cancer mortality. Lucence’s founding CEO Dr Min-Han Tan will discuss how Lucence is building an MCED to solve this worldwide cancer challenge.</p> <p data-bbox="340 743 939 855">Moderator: Professor Dean HO, <i>Provost’s Chair Professor; Director, The N.1 Institute for Health (N.1) and Director, The Institute for Digital Medicine (WisDM), NUS Medicine; Head, Department of Biomedical Engineering, NUS, Singapore</i></p>
5:30pm – 6:00pm	Free and easy time
6:00pm – 8:30pm	NIC members-only dinner

Speakers' and Moderators' Biographies



Professor Kishore MAHBUBANI

Chairman, NUS Medicine International Council (NIC)



Professor Kishore Mahbubani is a Distinguished Fellow at the Asia Research Institute (ARI), National University of Singapore (NUS).

Prof Mahbubani has been privileged to enjoy two distinct careers, in diplomacy (1971 to 2004) and in academia (2004 to 2019). He is a prolific writer who has spoken in many corners of the world.

In diplomacy, he was with the Singapore Foreign Service for 33 years (1971 to 2004). He had postings in Cambodia, Malaysia, Washington DC and New York, where he twice was Singapore's Ambassador to the UN and served as President of the UN Security Council in January 2001 and May 2002. He was Permanent Secretary at the Foreign Ministry from 1993 to 1998. As a result of his excellent performance in his diplomatic career, he was conferred the Public Administration Medal (Gold) by the Singapore Government in 1998.

Prof Mahbubani joined academia in 2004, when he was appointed the Founding Dean of the Lee Kuan Yew School of Public Policy (LKYSPP), NUS. He was Dean from 2004 to 2017, and a Professor in the Practice of Public Policy from 2006 to 2019. In April 2019, he was elected as an honorary international member to the American Academy of Arts and Sciences, which has honoured distinguished thinkers, including several of America's founding fathers, since 1780.

Mr Mahbubani was awarded the President's Scholarship in 1967. He graduated with a First Class Honours degree in Philosophy from the University of Singapore in 1971. From Dalhousie University, Canada, he received a Master's degree in Philosophy in 1976 and an honorary doctorate in 1995. He spent a year as a fellow at the Center for International Affairs at Harvard University from 1991 to 1992.

He has achieved several “firsts” in his two careers. He was the Founding Dean of the LKY School, the founding Director of the Civil Service College, the first Singapore Ambassador to serve on the UN Security Council, the first Singaporean to publish articles in globally renowned journals and newspapers like *Foreign Affairs*, *Foreign Policy*, the *New York Times* and the *Financial Times* and co-authored articles with distinguished global thought leaders like Kofi Annan, Klaus Schwab and Larry Summers. Mr Mahbubani has never shied away from taking on new challenges.

He has also been a prolific author, having published eight books: *Can Asians Think?*, *Beyond The Age Of Innocence*, *The New Asian Hemisphere*, *The Great Convergence*, *Can Singapore Survive*, *The ASEAN Miracle* (co-authored with Jeffery Sng), *Has the West Lost It?* and *Has China Won?*.

Prof Mahbubani has received significant international recognition for his many accomplishments. The Foreign Policy Association Medal was awarded to him in New York in June 2004 with the following opening words in the citation: “A gifted diplomat, a student of history and philosophy, a provocative writer and an intuitive thinker”. He was listed as one of the top 100 public intellectuals in the world by *Foreign Policy* and *Prospect* magazines in September 2005, and included in the March 2009 *Financial Times* list of Top 50 individuals who would shape the debate on the future of capitalism. He was selected as one of *Foreign Policy*’s Top Global Thinkers in 2010 and 2011. In 2011, he was described as “the muse of the Asian century”. He was selected by *Prospect* magazine as one of the top 50 world thinkers for 2014.

Professor Yap Seng CHONG

Lien Ying Chow Professor in Medicine and Dean, Yong Loo Lin School of Medicine, National University of Singapore



Professor Yap Seng Chong is the Dean of the National University of Singapore Yong Loo Lin School of Medicine (NUS Medicine), Singapore's first institute of higher learning and one of the leading medical schools in Asia. Since Prof Chong assumed the role of Dean in 2019, NUS Medicine has risen to rank 14th on the 2023 Times Higher Education World University rankings and 20th on the 2023 QS World University Rankings for Medicine.

In his recently appointed role as Deputy Chief Executive (Education and Research) of the National University Health System (NUHS), Prof Chong will be furthering NUHS' academic mission and augmenting the Academic Health System through his oversight of the academic and research development at all NUHS institutions.

As the former Executive Director (2015-2021) and now the Chief Clinical Officer at the Singapore Institute for Clinical Sciences, Agency for Science, Technology and Research (A*STAR), Prof Chong oversees clinical programmes that seek to promote health and human capacity in Singapore and the world. These programmes include the Growing Up in Singapore Towards healthy Outcomes (GUSTO) and the Singapore Preconception Study of long-Term maternal and child Outcomes (S-PRESTO) longitudinal studies that examine how conditions in pregnancy and early childhood influence the health and development of women and children.

In addition to his special research interest in the developmental origins of health and disease, Prof Chong has co-authored more than 500 research publications in top journals including The Lancet, the Journal of the American Medical Association (JAMA) and the British Medical Journal (BMJ). He received the National Outstanding Clinician Scientist Award from Singapore's Ministry of Health in 2017 for his research efforts in early human development and nutrition, and was recently conferred the Public Administration Medal (Silver) at the 2022 Singapore National Day Awards.

For the past few years, his energies have been focussed on helping develop national strategies to advance child and maternal health and well-being, promoting healthy living for families, and improving health resources equity in Singapore.

Prof Chong continues to care for mothers and babies in his role as a Senior Consultant in the Department of Obstetrics and Gynaecology at the National University Hospital (NUH) under the NUHS and, till today, still looks forward to welcoming newborn babies into the world.

Mr Casey MACE

Deputy Chief of Mission, US Embassy in Singapore



Mr Casey Mace began his assignment as the Deputy Chief of Mission (DCM) at the Embassy of the United States to the Republic of Singapore in July 2022. A career member of the Senior Foreign Service, Mr Mace has worked for the US Department of State for over twenty years, primarily focussed on US relations in the Indo-Pacific.

Mr Mace last worked on US-Singapore relations at the White House, where he served for two years on the National Security Council staff as the principal Southeast Asia advisor to President Obama and President Trump. In that role, he led US government preparations for the historic 2016 US-ASEAN Special Leaders' Summit in Sunnylands, CA and for the State Visit of Prime Minister Lee Hsien Loong to Washington to celebrate 50 years of US-Singapore relations. Immediately prior to his arrival in Singapore, Mr Mace served as the Deputy Chief of Mission and Chargé d'Affaires, a.i. at the US Embassy in Luxembourg from 2019-2022. Earlier in his career, Mr Mace served as the Deputy Political Counselor at the US Embassy in Jakarta, Political Unit Chief in the State Department's China office, and the Deputy Secretary of State's Special Assistant for East Asian and Pacific Affairs. Mr Mace has also served at the American Consulates in Sydney and Guangzhou.

Before joining the State Department, Mr Mace worked for a consultancy in the Space and Telecom industries. Mr Mace earned a bachelor's degree from Georgetown University, and he has studied Bahasa Indonesia and Mandarin Chinese for his career. He and his wife, Anne, have four children.

Mr Ryan ADOLPHSON

Chief Operating Officer, RWDC Industries, United States



Mr Ryan Adolphson is the Chief Operating Officer for RWDC responsible for global operations.

Previously Mr Adolphson served on the faculty of the University of Georgia where he was the Associate Director of New Materials Institute, Director of Pilot and Demonstration Programs as well as the Director of the University's Engineering Public Service and Outreach where he led numerous industry-scale development programs coordinating the design, construction and operation of research, pilot and commercial production facilities for companies and organisations in the energy, pulp and paper, textiles and food processing sectors. Ryan has worked for more than 25 years in the development of renewable bioproducts and advanced materials and technologies based on green engineering principles for industrial biotechnology applications.

Mr Adolphson holds a Bachelor of Science Degree in Biology and Master's Degree in Environmental Science and in Leadership and Communications.

Mr Adolphson has consulted widely on the development of renewable bioproducts and served as technical advisor to multi-national corporations, organisations and governments.

Dr Elisabeth ROIDER

Chief Scientific and Medical Officer and Partner, Maximon, Switzerland



Dr Elisabeth Roider is Harvard- and Swiss-trained, internationally renowned physician-scientist with a strong entrepreneurial background. She currently holds a position as an attending and principal investigator at the University Hospital of Basel, Switzerland, and a visiting scientist position at the Harvard Medical School in Boston, USA. Her scientific focus is in the areas of immunology, microbiology, biochemistry, redox biology and cell metabolism.

Dr Roider leads a multidisciplinary team including clinicians, basic scientists, machine learning specialists, mathematicians, statisticians, and epidemiologists, allowing a bench-to-bedside approach to solve complex, medical questions in the most efficient way. Her work has resulted in various high-impact publications, patents and awards, including the ground-breaking discovery of a novel mechanism of skin pigmentation.

Driven by the mission to identify and solve the most relevant medical and public health problems, Dr Roider co-founded the Swiss Venture Studio Maximon as a Partner where she serves as a Chief Scientific and Medical Officer. In this role she combines her clinical, scientific and entrepreneurial experience to support scientists and physicians in transforming true innovation into solid solutions and products, helping patients and consumers to achieve a better, healthier and longer life.

Dr Rob KONRAD

Chief Executive Officer and Founder, Biolytica, Switzerland



After starting his first company at the age of 15, over the past 25 years Dr Konrad has accumulated a broad range of experience in the fields of entrepreneurship, strategy and international management.

After consulting some of the leading health and pharmaceutical companies during his time with one of the BIG4 professional services firms, he served as Head of International Marketing for the leading Swiss retail group with over 25 individual companies, co-founded a software company and was CEO of two renowned companies in the field of International Health Insurance and Health Management or Medical Concierge Services.

As a longevity enthusiast and life-long tech geek, he believes the more you know about your body, the more you can improve your health and wellbeing, and is developing solutions and programs to help you do exactly that.

With Biolytica, his vision is to shape the future science of human health, making it more accessible, easier to understand, and real in benefit, to give as many people as possible access to a longer and healthier life.

Dr Konrad holds a doctorate in Public Healthcare Management.

Dr Suhina SINGH

Co-Founder and Chief Executive Officer, Jonda Health, Singapore.



Dr Suhina Singh is a Medical Doctor turned Digital Health Strategist, Investor and Entrepreneur bringing together Healthcare, Business and Technology expertise with over 15 years' experience in roles ranging from clinical practice, medical advisory and operations to data-driven marketing and digital innovation. She is passionate about building patient centred solutions through partnerships, investments and mentorships, and being a key driver of change in healthcare delivery. She utilises her unique

combination of skills to assist start-ups in achieving product market fit and facilitating scalability. More recently, Dr Singh spends her time on her own digital health start-up Jonda Health to positively make a difference in the lives of chronic disease patients such as herself.

In her spare time, Dr Singh is president of the INSEAD Alumni Emerging Markets Group which she helped to found in 2021 with fellow alumni where she works closely with the INSEAD Emerging Markets Institute and other organisations to facilitate the cross-pollination of knowledge across emerging markets.

Dr Singh holds a Bachelor of Medicine and Surgery from the University of Stellenbosch, a Masters in Science in International Health Management from Imperial Business School and an Executive MBA from INSEAD. She also holds a Lean 6 Sigma Green belt and has completed UX/UI and product management training. Dr Singh has recently attended the International Directors Programme at INSEAD to obtain her certificate in corporate governance.

Professor Brian KENNEDY

Distinguished Professor in Biochemistry and Physiology, Director of the Healthy Longevity Translational Research Programme, and the Asian Centre for Reproductive Longevity and Equality, Yong Loo Lin School of Medicine, National University of Singapore



Professor Brian K Kennedy is internationally recognised for his research in the basic biology of ageing and is a visionary committed to translating research discoveries into new ways of delaying, detecting, preventing, and treating human ageing and associated diseases. He is a Distinguished Professor in Biochemistry and Physiology at the Yong Loo Lin School of Medicine, National University of Singapore and serves as Director of (1) the Centre for Healthy Longevity at the National University Health System, (2) the NUS Medicine Healthy Longevity Translational Research Programme, and (3) the Asian Centre for Reproductive Longevity and Equality. Collectively, NUS ageing research seeks to demonstrate that longevity interventions can be successfully employed in humans to extend healthspan, the disease-free and highly functional period of life.

From 2010 to 2016, Prof Kennedy was the President and Chief Executive Officer of the Buck Institute for Research on Aging and he maintained a professorship there through 2020. Prof Kennedy has an adjunct appointment at the Department of Biochemistry, University of Washington, where he was a faculty member from 2001 to 2010. In addition, Prof Kennedy is also actively involved with a number of Biotechnology companies. In addition, Prof Kennedy serves as a Co-Editor- In-Chief at Aging Cell. Finally, Prof Kennedy has a track record of interaction in China, where he was a Visiting Professor at the Aging Research Institute at Guangdong Medical College from 2009 to 2014. His PhD was performed in the laboratory of Leonard Guarente at MIT, where he published the first paper linking Sirtuins to ageing.

Professor Steven ROSEFIELDE

Professor of Economics, University of North Carolina,
Chapel Hill, United States



Steven Rosefielde, Professor of Economics, University of North Carolina, Chapel Hill. He received his PhD from Harvard University, and is a Member of Russian Academy of Natural Sciences (RAEN).

His books include:

- Democracy and Its Elected Enemies: The West's Paralysis, Crisis and Decline, Cambridge University Press, 2013;
- The Kremlin Strikes Back: Russia and the West After Crimea's Annexation, Cambridge University Press, 2016;
- China's Market Communism: Challenges, Dilemmas, Solutions Routledge, 2017;
- The Unwinding of the Globalist Dream: EU, Russia and China, World Scientific, 2017;
- Putin's Russia: Economic, Political and Military Foundations, World Scientific, 2020,
- Beleaguered Superpower: Biden's America Adrift, (with Quinn Mills), World Scientific Publishers, 2021.

Mr Chandran NAIR

Founder and Chief Executive Officer, Global Institute For Tomorrow (GIFT), Hong Kong



Mr Chandran Nair is the Founder and CEO of the Global Institute For Tomorrow (GIFT), an independent pan-Asian think tank based in Hong Kong and Kuala Lumpur focussed on advancing a deeper understanding of global issues including the shift of economic and political influence from the West to Asia, the dynamic relationship between business and society, and the reshaping of the rules of global capitalism. He is the author of *Dismantling Global White Privilege: Equity for a Post-Western World*,

The Sustainable State: The Future of Government, Economy, and Society and *Consumptionomics: Asia's Role in Reshaping Capitalism and Saving the Planet* and the creator of *The Other Hundred*, a non-profit global photo journalism initiative to present a counterpoint to media consensus on some of today's most important issues.

Mr Nair was chairman of Environmental Resources Management (ERM) in Asia Pacific until 2004, establishing the company as Asia's leading environmental and sustainability consultancy.

Mr Nair is a member of WEF's Global Agenda Council on Governance for Sustainability and Experts Forum. He sits on the Executive Committee of the Club of Rome, the world's premier scientific think tank, is a member of the Global Advisory Board of Ethical Markets and is a Senior Fellow of CIMB ASEAN Research Institute (CARI), as well as a Fellow of the Royal Society of Arts. He is also an Advisor to the Royal Government of Cambodia on development issues.

Mr Nair has served as Adjunct Professor at the Hong Kong University of Science and Technology and is a former Advisor to ORIX Corporation, Asia's largest non-banking financial institution and a former member of the Global Stakeholder Advisory Council for BASF, the world's largest chemical company.

Mr Narinder J. SINGH

Co-Founder and Director, Avina Holdings, Singapore



Mr Narinder Singh is an experienced technology entrepreneur and investor with a demonstrated history of founding start-ups and scaling them to global presence. His most recent successful exit was Utopia Global, Inc (USA), a worldwide leader in enterprise data management solutions. Mr Singh is passionate about working with founders who want to grow and scale their companies globally. As a co-founder and Chief Operating Officer (COO), he has deep expertise working across strategy, new markets expansion and global operations. In addition, he has a track record of successfully raising funds from private equity and growth investors.

In 2003, Mr Singh co-founded Utopia Global, Inc, where he was a Member of the Board and Chief Operating Officer. Utopia became one of only 30 companies globally to become an SAP Software Solution Extension partner, and the firm's software was implemented by several Fortune 100 companies. As COO, Mr Singh expanded Utopia beyond North America to Europe, Middle East, India, Southeast Asia, and Australia and New Zealand (ANZ), and grew the firm to over 650 employees. Utopia was acquired in late 2020 by Prometheus Group, a portfolio company of Genstar Capital, a leading private equity firm with \$19 billion in assets under management (AUM).

Mr Singh is an active participant in the Singapore start-up eco system. He invests primarily in tech-oriented start-ups, and mentors founders in scaling up into regional and global markets.

Mr Singh has a deep and enduring commitment to philanthropy. At Utopia he spearheaded the annual Joy of Giving programme which supported causes in local communities. He currently leads his family's philanthropic programmes which are focussed on improving access to high quality education for children from underprivileged families.

Mr George YEO

Former Minister of Foreign Affairs, Singapore and currently Visiting Scholar at the Lee Kuan Yew School of Public Policy of the National University of Singapore



Mr George Yeo is currently a Visiting Scholar at the Lee Kuan Yew School of Public Policy of the National University of Singapore, and the Founding Patron of its Asia Competitiveness Institute.

Mr Yeo was with Kerry Group in Hong Kong from 2012 to 2021. He was Chairman and Executive Director of Kerry Logistics Network from 2012 to 2019.

From September 1988 to May 2011, he served 23 years in the Singapore Government, and was Minister for Information and the Arts, Minister for Health, Minister for Trade and Industry and Minister for Foreign Affairs.

Mr Yeo studied Engineering at Cambridge University on a President's Scholarship, graduating with a Double First in 1976, and became a Signals Officer in the Singapore Armed Forces. After graduating from the Singapore Command and Staff College in 1979, he was posted to the Republic of Singapore Air Force. He graduated with an MBA (Baker Scholar) from the Harvard Business School in 1985. He was appointed Chief-of-Staff of the Air Staff (1985-1986) and Director of Joint Operations and Planning in the Defence Ministry (1985-1988), attaining the rank of Brigadier-General.

Mr Yeo was Member of the Pontifical Commission for Reference on the Economic-Administrative Structure of the Holy See in 2013-2014 and the Vatican Council for the Economy from February 2014 to July 2020.



Mr Yeo is a member of the Board of Trustees of Berggruen Institute on Governance, International Advisory Panel of Peking University, Senior Advisory Council of Beijing Forum, International Advisory Board of IESE Business School, International Advisory Council of China's Eco Forum Global Guiyang, International Advisory Board of Japan's National Graduate School for International Policy Studies (GRIPS), International Advisory Committee of Mitsubishi Corporation, Global Advisory Board of MUFG, the External Advisory Board of the European University Institute's School of Transnational Governance and the Board of Governors of the Singapore Manufacturing Federation. Mr Yeo is an Independent Non-Executive Director of AIA Group listed on the Hong Kong Stock Exchange and Pinduoduo listed on NASDAQ and Creative Technology listed on the Singapore Stock Exchange. He is an advisor to Brunswick for its Geopolitical Initiative, Singapore's V3 Group, Huawei International Pte Ltd in Singapore, Winning International Group and a small start-up called Plantonic.

He is Patron of LASALLE College of the Arts and the Eurasian Association, and Advisor to the Sun Yat-Sen Nanyang Memorial Hall. Mr Yeo was the Conference Chairman of the Singapore Summit from 2012 to 2016.

Mr Mark CUTIS

Non-Executive Chairman and Managing Partner, CCHL



Mr Mark Cutis is a seasoned Banking and Capital Markets Executive with extensive global experience having actively managed portfolios of assets as both CIO and CEO on behalf of both private and state-owned capital managers, with an outstanding record of profitability.

Most recently, Mark was the CEO of ADGM Authority, Abu Dhabi Global Market, Group CFO, and Chief Advisor of Abu Dhabi National Oil Company, and immediately prior to that was the founding CIO of Global Situations at Abu Dhabi Investment Council, a Middle East Sovereign Wealth Fund. Mark has also run investment managers and financial institutions in London, Tokyo, Frankfurt, Moscow, and New York.

Executive Experience

- Chief Executive Officer, ADGM Authority, Abu Dhabi Global Market Authority
- Chief Advisor, Finance and Investments, Abu Dhabi National Oil Company
- Group Chief Financial Officer, Abu Dhabi National Oil Company
- Chief Investment Officer- Special Situations, Abu Dhabi Investment Council
- Chief Investment Officer, Tokyo, Shinsei Bank
- CEO Japan Asian Management Committee, Tokyo, HVB AG (Now Unicredito)
- Treasurer and Managing Director, Americas Management Committee, New York, HVB AG (Now Unicredito)
- President, New York, Allied Capital Asset Management
- Managing Director International Markets Management Committee, London, Nomura International, PLC
- Treasurer, London, EBRD
- Deputy Treasurer, Investments, London, EBRD
- Direktor in der Bank, Frankfurt, DRESDNER BANK AG
- Managing Director Executive Committee, London, Merrill Lynch

Education and Professional Qualifications

- MBA, Finance, Wharton Scholarship, Wharton Business School
- Bachelor of Arts, Monetary Economics and History, Emory University
- Elective work in Mathematics and German, Munich Campus, University of Maryland

Dr Kian Chung LEE

Chief Executive Officer, BioCheetah



Dr Lee Kian Chung has 22 years of experience in the life sciences industry especially in the field of molecular biology and proteomic applications, and wide exposure to the various technologies that are currently being used in both academic and industrial settings.

Dr Lee graduated from the National University of Singapore (NUS) in 2000 with a PhD degree in Molecular Biology. He had subsequently worked as a Research Fellow in NUS's Department of Biological Sciences from the year 2000 till 2004 utilising various techniques in proteomics, molecular biology and recombinant DNA for virus characterisation. From year 2005 onwards, he had developed and characterised a set of antibody reagents in Sir David Lane's p53 Tumor Suppressor Laboratory in Institute of Molecular and Cell Biology (IMCB, A*STAR) of which he had licensed to a major international antibody provider. When Sir David Lane founded the Experimental Therapeutics Centre (ETC, A*STAR) in 2007, Dr Lee was tasked with setting up the Antibody Development Unit and ensuring its smooth operation. During this time, he was exposed to the various stages of product development, especially protein biologics whereby he had been heavily involved from selection of target products to product synthesis and commercialisation of the final products. In ETC, he managed a team of scientists and handled several key projects concurrently. In 2009, Dr Lee joined Schering-Plough's Translational Medicine Research Centre (TMRC) whereby he led the Biochemistry group in providing scientific leadership and line responsibility for all projects that required biomarker discovery and identification efforts. He was the Singapore team lead for collaboration projects that required his expertise and the capabilities of his group for protein biomarkers. These projects were mainly kinase activity profiling and development of biomarker assays for assessing target engagement and pharmacodynamics following administration of new drug compounds. In 2010, Merck Sharp & Dohme acquired Schering-Plough and he was additionally assigned the task of coordinating the setup of immunohistochemistry and automation in TMRC.

In 2014, Dr Lee joined back IMCB A*STAR whereby his research focus was to translate the discoveries from bench to clinical applications especially in immunodiagnosics. Besides managing collaborations that involve the identification of important biomarker targets and generation of antibodies for both diagnostic and therapeutic purposes in IMCB, he was also responsible for development of new technologies that will enhance the generation of novel and commercially viable monoclonal antibodies. He also worked on product development for immunoassays targeting various urological cancers and this was performed in close collaboration with various clinicians in Singapore, France, Korea, and China hospitals. In 2018, Dr Lee co-founded BioCheetah Pte Ltd together with Prof. Jean Paul Thiery to develop and commercialise non-invasive, protein-based diagnostic applications. The first diagnostic applications in development are based on the proprietary bladder cancer biomarkers and detection antibodies discovered and developed in IMCB by both Jean Paul and Dr Lee. Since 2019, he had been the CEO of BioCheetah Pte Ltd and concurrently manages Prof Thiery's R&D laboratory in IMCB.

Mr Toby SIMON

Chief Executive Officer, Synergia Foundation and Synergia Bio Sciences, India



Mr Toby Simon is the Founder and President of Synergia Foundation, a strategic think tank and business incubation company that works to develop impactful insights and solutions in the areas of geopolitics, advanced technologies and geo security.

He is President of Synergia Bio Sciences (SBS), company that focusses on translation research. SBS has developed an intra nasal nano technology platform that can deliver drugs to the Central Nervous System

He is a university topper, has a master's in business administration, a graduate of the Harvard Business School, a research associate at the Massachusetts Institute of Technology. He is currently pursuing his doctoral studies in International Security.

Dr Yvanka GILLIAM

Chief Executive Officer and Founder, Clinical Research Advancement, Singapore



Dr Yvanka Gilliam is the Chief Executive Officer (CEO) and Founder of Clinical Research Advancement. She has over 23 years of clinical research, medical affairs, and health outcomes experience with a focus on emerging markets.

Dr Gilliam has served as the Vice President (VP) of Operations for Diaceutics within the Asia Pacific, Middle East and Africa regions. Before joining Diaceutics, she was the VP of Clinical Affairs and Real World Evidence (RWE) with Kantar Health. She has also served as the Head of Real World Evidence at IQVIA Singapore.

Dr Gilliam has worked in clinical operations, medical affairs, health economics outcomes research (HEOR), and market access roles within the Pharmaceutical, Biotechnology, and Diagnostic industries.

Her early career focussed on the successful launch of novel Oncology compounds in the US and Latin America where she collaborated on the successful launch of 9 (nine) novel Oncology compounds and a companion diagnostic.

She serves as a key advisor and member of the LUNGeivity research collaboration with the Food and Drug Administration (FDA), and as an advisor and board member of Jonda Health.

Dr Gilliam is passionate about the advancement of clinical research initiatives that support health equity, improve patient outcomes and result in the generation of real-world evidence.

Under her leadership, Clinical Research Advancement has become a trusted partner for clients seeking efficient, reliable, and high-quality clinical research services.

Dr Gloryn CHIA

Assistant Professor, National University of Singapore



Dr Gloryn Chia is an Assistant Professor at the Department of Pharmacy, National University of Singapore, and a Principal Investigator at iHealthtech. She obtained her PhD from the University of Cambridge under the Wellcome Trust Scholarship, and went on to complete her postdoctoral training at Columbia University under the ASTAR International Fellowship. In 2019, she was awarded the National Research Fellowship, and in 2021, she was named one of two female scientists to receive the L'Oréal Singapore for Women in Science Fellowship. Her current research interests include developing neoantigen vaccines for treating solid tumors and discovering novel immunotherapies to overcome refractory cancers.

Dr Snehal PATEL

Managing Director, Saena Partners, Singapore



Dr Snehal Patel is the Managing Director of Saena Partners, a venture incubation firm based in Singapore. In that capacity, he has co-founded five venture-backed companies, and most recently served as CEO and Co-Founder of MyDoc, Southeast Asia's first regional telemedicine company, which the firm exited last year.

A Kauffman Fellow and 6X Forbes Asia 30-under-30 judge, Dr Patel moved to Singapore from the US to found and lead the healthcare team at the Clermont Group, a multi-billion dollar investment fund, where he led the procurement and management of investments across South and Southeast Asia. Prior to the work at the Clermont Group, he practiced law at Cravath, Swaine & Moore, LLP in New York City. Dr Patel received an MD and a JD from Columbia University and served as a Clinical Fellow at the Harvard Medical School. In addition to multiple board and advisor roles, he currently serves as Advisor to Harvard Medical School's Center for Primary Care HealthTech Fellowship Program as well as the Columbia University Vagelos College of Physician and Surgeons' International Collaboration and Exchange Program.

Dr Min Han TAN

Chief Executive Officer and Medical Doctor, Lucence



Dr Min-Han Tan is the Founder, CEO and Medical Director of Lucence. The Company develops advanced liquid biopsy blood tests that profile the hallmarks of cancer to the deepest limit to achieve timely tailored treatment and earlier detection. Headquartered in Singapore and Palo Alto, California, with offices in Hong Kong and Suzhou, its clinical services are delivered worldwide through twin CAP-accredited, CLIA-licensed laboratories in the US and Singapore.

Dr Tan received his medical degree and PhD from the National University of Singapore, graduating with gold medals. He completed two specialist medical oncology and clinical cancer genetics fellowships at the National Cancer Centre Singapore and the Cleveland Clinic, US, respectively. He joined the Agency for Science, Technology and Research (A*STAR), Singapore in 2011 to lead the Laboratory of Systems Medicine. Dr Tan subsequently founded Lucence in 2016 to commercialise the liquid biopsy technologies that his lab developed at A*STAR.

Professor Dean HO

Provost's Chair Professor; Director, The N.1 Institute for Health (N.1); Director, The Institute for Digital Medicine (WisDM); Head, Department of Biomedical Engineering, Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore



Professor Dean Ho is currently Provost's Chair Professor, Director of The Institute for Digital Medicine (WisDM) at the Yong Loo Lin School of Medicine; Director of The N.1 Institute for Health (N.1), and Head of the Department of Biomedical Engineering at the National University of Singapore.

Prof Ho and collaborators successfully developed and validated CURATE.AI, a powerful artificial intelligence platform that personalises human treatment for a broad spectrum of indications ranging from oncology, to digital therapeutics and infectious diseases, among others. His team also developed IDentif.AI to optimise combination therapy design against SARS-CoV-2 and to address antimicrobial resistance. Recently, his team unveiled WisDM Green, a technology platform to sustainably address food security and optimise yield while preserving nutritional content.

Prof Ho is an elected Fellow of the US National Academy of Inventors (NAI), American Association for the Advancement of Science (AAAS), the American Institute for Medical and Biological Engineering (AIMBE), and the Royal Society of Chemistry. He was also recently named to the HIMSS Future50 Class of 2021 for his internationally-recognised leadership in digital health. Prof Ho is also a Subgroup Lead in the World Health Organization (WHO) Working Group for the regulation of AI for Health.



Prof Ho is an author of the forthcoming book, *Medicine Without Meds*, which is being released internationally. The book serves as a blueprint for a broad community – from business leaders and venture capitalists to healthcare systems – on how to accelerate practice-changing innovation to patients and caregivers. All author proceeds from the book will be benefiting the WisDM Patient Impact Fund.

Prof Ho has appeared on the National Geographic Channel Program “Known Universe,” and Channel News Asia’s “The Hidden Layer: Healthcare Trailblazers”. His discoveries have been featured on CNN, The Economist, National Geographic, Forbes, Washington Post, NPR and other international news outlets.

Prof Ho is a recipient of the Tech Heroes from Crisis Pathfinder Award from the Singapore Computer Society, NSF CAREER Award, Wallace H Coulter Foundation Translational Research Award, and V Foundation for Cancer Research Scholar Award, among others. He has also served as the President of the Board of Directors of the Society for Laboratory Automation and Screening (SLAS), a leading global drug development organisation.

Acknowledgements

The NUS Medicine International Council wishes to thank all speakers, moderators, and discussants for taking part in the Singapore Conference 2023. The Council is also grateful to the many individuals who assisted in the planning and implementation of the conference.

General Information

DISCLAIMERS

House Rule: NUS Medicine International Council (NIC) events take place under the Chatham House Rule. However, photographs, images and videos may be taken during the event and may be used on our social media, marketing and communications platforms under the NUS Yong Loo Lin School of Medicine and the National University of Singapore umbrella. You shall be deemed to have consented to our collection, use and disclosure of the photographs, images and videos to third parties. You accept the above-mentioned conditions by attending the event.

Insurance and Liability: The organising committee cannot accept liability for personal injury, loss or damage to the belongings of meeting participants, either during or as a result of the meeting.

All information provided in the programme is accurate at the time of printing and is subject to changes. The NIC will not be responsible for any changes in the programme due to external unforeseen circumstances and reserves the right to cancel, postpone, relocate or change any of the sessions.

Useful Contacts



Conference Hotel

Four Seasons Hotel Singapore

190 Orchard Boulevard, Singapore 248646

Phone: +65 6734 1110

Taxi Service

Taxi ride between Changi Airport and Four Seasons Hotel Singapore takes approximately 30 minutes and costs around S\$25 - S\$35. Private hire cars like Grab, Gojek and TADA are also commonly used.

Comfort Taxi / CityCab (ComfortDelgro Taxi)

CDG Zig App

Hotline: +65-6552 1111

SMRT Taxi

Hotline:

+65-6555 8888

Trans Cab

Hotline:

+65 6555 3333

Emergency

Hotel Security Department:

+65-6831 7180

Front Office Desk:

+65-6831 7340

Ambulance / Fire:

995

Police:

999

NIC Contact

Ms Ng Hwee Koon:

+65-9018 7398

Ms Jenny Koh:

+65-9666 1227



International Council
Yong Loo Lin School of Medicine

